Vnitr Lek 2010, 56(Suppl 1):81-90

Thrombocytopenia in patients with proved antiphospholipid antibodies or with antiphospholipid syndrome

A. Buliková1,*, D. Haruštiaková2, J. Zavřelová1, L. Dušek2, M. Penka1
1 Oddělení klinické hematologie FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Miroslav Penka, CSc.
2 Institut biostatistiky a analýz Lékařské a Přírodovědecké fakulty MU Brno, přednosta doc. RNDr. Ladislav Dušek, CSc.

Thrombocytopenia in patients with antiphospholipid antibodies (APA) is relative common finding which is found in approximately 20-40% of cases. There are likely different mechanisms resulting in thrombocytopenia in these situations. Authors summarise current knowledge of pathophysiology, clinical manifestations and management of APA-associated thrombocytopenia and other causes of decreased value of peripheral blood platelets in APA positive persons.

Keywords: thrombocytopenia; antiphospholipid antibodies; pathophysiology; treatment

Received: March 24, 2010; Published: February 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Buliková A, Haruštiaková D, Zavřelová J, Dušek L, Penka M. Thrombocytopenia in patients with proved antiphospholipid antibodies or with antiphospholipid syndrome. Vnitr Lek. 2010;56(Supplementum 1):81-90.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Harris EN, Asherson RA, Gharavi AE et al. Thrombocytopenia in SLE and related autoimmune disorders: Association with anticardiolipin antibodies. Br J Haematol 1985; 59: 227-230. Go to original source... Go to PubMed...
    2. Harris EN, Cahn JKH, Asherson RA et al. Thrombosis, recurrent fetal loss, and thrombocytopenia. Arch Intern Med 1986; 146: 2153-2156. Go to original source...
    3. Asherson RA, Khamashta M, Ordi-Ros J. The "primary" antiphospholipid syndrome. Major clinical and serological features. Medicine 1989; 68: 366-375. Go to original source... Go to PubMed...
    4. Alacrón-Segovia D, Pérez-Vézquez ME, Villa AR et al. Preliminary classification criteria for the antiphospholipid syndrome within systemic lupus erythematosus. Sem Arthr Rheumat 1992; 21: 275-285. Go to original source... Go to PubMed...
    5. Pierangeli SS, Chen PP, Raschi E et al. Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenetic mechanisms. Semin Throm Hemost 2008; 34: 236-250. Go to original source... Go to PubMed...
    6. Pennings MTT, Derksen RHWM, van Lummel M et al. Platelet adhesion to dimeric β2-glycoprotein I under conditions of flow is mediated by at least two receptors: glycoprotein Ibα and apoliporotein E receptor 2'. J Thromb Haemost 2007; 5: 369-377. Go to original source... Go to PubMed...
    7. Miyakis S, Lockshin MD, Atsumi T et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306. Go to original source... Go to PubMed...
    8. McNeil HP, Simpson RJ, Chesterman CN et al. Anti-phospholipid antibodies are directed a complex antigen that includes a lipid-binding inhibitor of coagulation. Proc Natl Acad Sci 1990; 87: 4120-4124. Go to original source... Go to PubMed...
    9. Galli M, Comfurius P, Maassen C et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990: 335: 1544-1547. Go to original source... Go to PubMed...
    10. Matsuura E, Igarashi Y, Fujimoto M et al. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet 1990; 336: 177-178. Go to original source... Go to PubMed...
    11. Roubey RAS. Mechanisms of autoantibody-mediated thrombosis. Lupus 1998; 7: 114-119. Go to original source... Go to PubMed...
    12. Pierangeli SS, Chen PP, Gonzalez EB. Antiphospholipid antibodies and the antiphospholipid syndrome: an update on treatment and pathogenic mechanisms. Curr Opin in Hematology 2006; 13: 366-375. Go to original source... Go to PubMed...
    13. Giannakopoulos B, Passam F, Rahgozar S et al. Current concepts on the pathogenesis of the antiphospholipd syndrome. Blood 2007, 109; 422-430. Go to original source... Go to PubMed...
    14. Meroni PL. Pathogenesis of the antiphospholipid syndrome: An additional example of the mosaic of autoimmunity. Blod 2008; 30: 99-103. Go to original source... Go to PubMed...
    15. Raschi E, Testoni C, Bosisio D et al. Role of the MyD66 transduction signaling pathway in endothelial activation by antiphospholipid antibodies. Blood 2003; 101: 3495-3500. Go to original source... Go to PubMed...
    16. Vega-Ostertag M, Casper K, Swerlick R et al. Involvement of p38 MAPK in the up-regulation of tissue factor on endothelial cells by antiphospholipid antibodies. Arthritis Rheumat 2005; 52: 1545-1554. Go to original source... Go to PubMed...
    17. Holers VM, Girardi G, Mo L et al. C3 activation is required for antiphospholipid antibody-induced fetal loss. J Ex Med 2002; 1995: 211-220. Go to original source... Go to PubMed...
    18. Redecha P, Tilley R, Tencati M et al. Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury. Blod 2007; 110: 2423-2431. Go to original source... Go to PubMed...
    19. Arnout J. The pathogenesis of the antiphospholipid syndrome: a hypothesis based on parallelisms with heparin-induces thrombocytopenia. Thromb Haemost 1996; 75: 536-541. Go to original source... Go to PubMed...
    20. Vermylen J, Hoylaerts MF, Arnout J. Antibody-mediated thrombosis. Thromb Haemost 1997; 78: 420-426. Go to original source... Go to PubMed...
    21. Arnout J, Vermylen J. Current status and implication of autoimmune antiphospholipid antibodies in relation to thrombotic disease. J Throm Haemost 2003; 1: 931-942. Go to original source... Go to PubMed...
    22. Arnout J. The pathogenesis of the antiphospholipid syndrome: a hypothesis based on parallelisms with heparin-induced thrombocytopenia. Thromb Haemost 1996; 78: 420-426. Go to original source...
    23. Pennings MTT, Derksen RHWM, van Lummer M et al. Platelet adhesion to dimeric β2-glycoprotein I under conditions of flow is mediated by at least two receptors: glycoprotein Ibα and apoliprotein E receptor 2'. J Throm Haemost 2007; 5: 369-377. Go to original source... Go to PubMed...
    24. Urbanus RT, Pennings MTT, Derksen RHWM et al. Platelet activation by dimeric β2-glycoprotein I requires signaling via both glycoprotein Ibα and apolipoprotein E receptor 2'. J Thromb Haemost 2008; 6: 1405-1412. Go to original source... Go to PubMed...
    25. Lutters BCH, Derksen RHWM, Tekelenburg WL et al. Dimers of β2-Glykoprotein I increase platelet deposition to collagen via interaction with phospholipids and the apolipoprotein E receptor 2'. J Biolog Chem 2003; 278: 33831-33838. Go to original source... Go to PubMed...
    26. van Lummel M, Pennings MTT, Derksen RHWM et al. The binding site in β2-glycoprotein I for ApoER2' on platelet is located in domain V. J Biological Chem 2005; 280: 36729-36736. Go to original source... Go to PubMed...
    27. Shi T, Giannakopoulos B, Yan X et al. Anti-β2-glykoprotein I antibodies in complex with - β2-glykoprotein I can activate platelets in a dysregulated manner via glycoprotein Ib-IX-V. Artritis Rheumat 2006; 54: 2558-2567. Go to original source... Go to PubMed...
    28. Vega-Ostertak ME, Ferrata DE, Romay-Penabad Z et al. Role of p38 mitogen-activated protein kinase in antiphospholipid antibody-mediated thrombosis and endothelial cell activation. J Thromb Haemost 2007; 5: 1828-1834. Go to original source... Go to PubMed...
    29. Hulstein JJJ, Lenting PJ, de Laat B et al. β2-glycoprotein I inhibits von Willebrand factor-dependent platelet adhesion and aggregation. Blood 2007; 110: 1483-1491. Go to original source... Go to PubMed...
    30. Hulstein JJJ, de Groot PG, Silence K at al. A novel nanobody that detects the gain-of-function phenotype of von Willebrand factor in ADAMTS13 deficiency and von Willebrand disease type 2B. Blood 2005; 106: 3035-3042. Go to original source... Go to PubMed...
    31. Stasi R, Stipa E, Masi M et al. Prevalence and clinical significance of elevated antiphospholipid antibodies in patients with idiopatic thrombocytopenic purpura. Blood 1994; 84: 4203-4208. Go to original source...
    32. Diz-Kücükkaya R, Hacihanefioglu A, Yenerel M et al. Antiphospholipid antibodies and antiphospholipid syndome in patients presenting with immune thrombocytopenic purpura: a prospective cohort study. Blood 2001; 98: 1760-1764. Go to original source... Go to PubMed...
    33. Bidot CJ, Jy W, Horstman LJ et al. Antiphosholipid antibodies in immune thrombocytopenic purpura tend to emerge in exacerbation and decline in remission. British J Haematol 2004; 128: 366-372. Go to original source... Go to PubMed...
    34. Atsumi T, Furukawa S, Amengual O et al. Antiphospholipid antipody associated thromocytopenie and the paradoxical risk of thrombosis. Lupus 2006; 14: 499-504. Go to original source... Go to PubMed...
    35. Wilson WA, Gharavi AE, Koike T et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. Arthritis Rheumat 1999; 42: 1309-1311. Go to original source...
    36. Macchi L, Rispal P, Clofent-Sanchez G et al. Anti-platelet antibodies in patients with systemic lupus erythematosus and primary antiphopholipid antibody syndrome: their relationship with observed thromocytopenia. British J Haematol 1997; 98: 336-341. Go to original source... Go to PubMed...
    37. Jimenez JJ, Jy W, Mauro LM et al. Transendothelial migration of leukocytes is promoted by plasma from a subgroup if immune thrombocytopenic purpura patients with small-vessel ischemic brain disease. Am J Hematol 2008; 83: 206-211. Go to original source... Go to PubMed...
    38. Dunoyer-Geindre S, Bochlen F, Favier R et al. Endothelial cell activation by immunuglobulins from patients with immune thromobcytopenic purpura or with antiphopholipid syndrome. Haematologica 2008; 84: 635-636. Go to original source... Go to PubMed...
    39. Bizzato N, Brandaliase M. EDTA-dependent pseudothrombocytopenia. Association with antiplatelet and antiphospholipid antibodies. Am J Clin Patol 1995; 103; 103-107. Go to original source... Go to PubMed...
    40. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med. 2002; 346: 995-1008. Go to original source... Go to PubMed...
    41. Go RS, Johnston KL, Bruden KC. The association between platelet autoantibody specificity and response to intravenous immunoglobulin G in the treatment of patients with immune thromobcytopenie. Haematologica 2007; 92: 283-284. Go to original source... Go to PubMed...
    42. Ollsson B, Andersson PD, Jernas M et al. T-cell mediated lysis of autologous platelets in chronic thromocytopenic purpura. Nat Med 2003; 9: 1123-1124. Go to original source... Go to PubMed...
    43. Zang F, Chu X, Wang L et al. Cell-mediated lysis of autologous platelets in chronic idiopathic thrombocytopenic purpura. Eur J Haematol 2006; 76: 427-431. Go to original source... Go to PubMed...
    44. McMillian R, Wang L, Tomer A et al. Suppression of in vitro megakaryocyte production by antiplatetet autoantibodies from adult patients with chronic ITP. Blood 2004; 103: 1364-1369. Go to original source... Go to PubMed...
    45. Cervera R, Khamashta MS, Font J et al. Systemic lupus erythematosus: Clinical and immunological patterns of disease expression in a cohort of 1000 patients. Medicine 1993; 72: 113-124. Go to original source... Go to PubMed...
    46. Cuadrado MJ, Mujic F, Muňoz E et al. Thrombocytopenia in the antiphospholipid syndrome. Ann Rheum Dis 1997; 56: 194-196. Go to original source... Go to PubMed...
    47. Aster RH, Bougie DW. Drug-induced immune thrombocytopenia. N Engl Med 2007; 357: 580-587. Go to original source... Go to PubMed...
    48. Gruel Y, Rupin A, Watier H et al. Anticardiopipin antibodies in heparin-associated thrombocytopenia. Thromb Res 1992; 67: 601-606. Go to original source... Go to PubMed...
    49. Socher I, Kroll H, Jorsk S et al. Heparin-independent activation of platelet by heparin-induced thrombocytopenia antibodies: a common occurrence. J Thromb Haemost 2008; 6: 197-200. Go to original source... Go to PubMed...
    50. Pauzner R, Greinacher A, Selleng K et al. False-positive tests for heparin-induced thrombocytopenia in patients with antiphospholipid syndrome and systemic lupus erythematosus. J Tromb Haemost 2009; 7: 1070-1074. Go to original source... Go to PubMed...
    51. Martion-Toutain I, Piette JC, Diewmert MC et al. High prevalence of antibodies to platelet factor 4 heparin in patients with antiphospholipid antibodies in absence of heparin induced thromocytopenia. Lupus 2007; 16: 79-83. Go to original source... Go to PubMed...
    52. Lo GK, Sigouin ChS, Warkentin TE. What is the potential overdiagnosis of heparin-induced thrombocytopenia. Am J Hematol 2007; 82: 1037-1043. Go to original source... Go to PubMed...
    53. Warkentin TE. Antiphospholipid and anti-PF4 antibodies: an association affecting anti-PF4/ heparin assay analysis. J Thromb Haemost 2009; 7: 1067-1069. Go to original source... Go to PubMed...
    54. Espinosa G, Bucciarelli S, Cervera R et al. Thrombotic microangiopathic haemolytic anaemia and antiphospholipid antibodies. Ann Rheum Dis 2004; 63: 730-736. Go to original source... Go to PubMed...
    55. Fojtík Z, Kořístek Z, Klabussay M et al. Recidivující trombotická trombocytopenická purpura u nemocné se systémovým lupus erythermatodes. Čes Revmatol 2003; 11: 157-160.
    56. Cervera R, Font J, Gómez-Puerta JA et al. Validation of the preliminary criteria for the classification of catastrophic antiphosholipid syndrome. Ann Rheum Dis 2005; 64: 1205-1209. Go to original source... Go to PubMed...
    57. Asherson RA, Pierangeli S, Cervera R. Is there a microangiopathic antiphospholipid syndrome? Ann Rheum Dis 2007; 66: 429-432. Go to original source... Go to PubMed...
    58. Asherson RA, Pierangeli S, Cervera R. Microangiopathic antiphospholipid-associated syndromes revisited - new concepts relating to antiphospholipid antibodies and syndromes. J Rheumatol 2007; 34: 1793-1795. Go to PubMed...
    59. Galli M, Finazzi G, Barbui T. Thromocytopenia in the antiphospholipid syndrome. Br J Haematol 1996; 93: 1-5. Go to original source... Go to PubMed...
    60. Finazzi G. The Italian registry od antiphospholipid antibodies. Haematologica 1997; 82: 101-105. Go to PubMed...
    61. Vianna JL, Khamashta MA, Ordi-Ros J et al. Comparison of the primary and secondary antiphospholipid syndrome: European multicentre study of 114 patients. Am J Med 1994; 96: 3-9. Go to original source... Go to PubMed...
    62. Buliková A, Haruštiaková D, Zavřelová J et al. Long-term follow-up in patients with positive antiphospholipid antibodies - single centre experience. J Thromb Haemost 2009; Suppl. 2: PP-MO-259.
    63. Leuzzi RA, Davis GH, Cowchock FS et al. Management of immune thromobocytopenic purpura associated with the antiphospholipid antibody syndrome. Clin Exp Rhematol 1997; 15: 197-200.
    64. Galli M, Barbui T. Management of thrombocytopenia in Hughes syndrome. In: Khamashta MA (Ed.) Hughes syndrome. London: Springer Verlag 2000; 408-418. Go to original source...
    65. Lim W. Antiphospholipid syndrome. Hematology (Am Soc Hematol Edu Program) 2009: 233-239. Go to original source... Go to PubMed...
    66. Galindo M, Khamashta MA, Hughes GRV. Splenectomy for refractory thrombocytopenia in the antiphospholipid syndrome. Rheumatology 1999; 38: 848-853. Go to original source... Go to PubMed...
    67. Garvey B. Rituximab in the treatment of autoimmune haematological disorders. Br J Heaematol 2008; 141: 149-169. Go to original source... Go to PubMed...
    68. Ruckert A, Glimm H, Lubbert M et al. Successful treatment of life-threatening Evans syndrome due to antiphospholipid antibody syndrome by rituximab-based regimen: a case with long-term follow-up. Lupus 2008; 17: 757-760. Go to original source... Go to PubMed...
    69. Snowden JA, Martin-Rendon E, Watt SM. Clinical stem cell therapies for severe autoimmune diseases. Transfusion medicine 2009; 19: 223-234. Go to original source... Go to PubMed...
    70. Orita T, Tsunoda H, Yabuta N et al. A novel therapeutic approach for thrombocytopenia by miniantibody agonist of the thrombopeitein receptor. Blood 2005; 105: 562-566. Go to original source... Go to PubMed...
    71. Kavanaugh A. Danazol therapy in thrombocytopenia associated with the antiphospholipid antibody syndrome. Ann Int Med 1994; 121: 767-768. Go to original source... Go to PubMed...
    72. Durand JM, Lefevre P, Kaplanski G et al. Correction of thromocytopenia with dapson in the primary antiphospholipid syndrome. J Rheumatol 1993; 20: 1777-1778. Go to PubMed...
    73. Dunoyer-Geindre S, Kruithof EKO, Boehledn F et al. Aspirin inhibits endothelial cell activation induced by antiphospholipid antibodies. J Throm Haemost 2004; 2: 1176-1181. Go to original source... Go to PubMed...
    74. Erkan D, Harrison MJ, Levy R et al. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome. Arthritis and rheumatism 2007; 56: 2382-2391. Go to original source... Go to PubMed...
    75. Alliot C, Messouak D, Albert F. Correction of thromocytopenia with aspirin in the primary antiphospholipid syndrome. Am J Hematol 2001; 68: 215-217. Go to original source... Go to PubMed...
    76. Rand JH, Wu X-X, Quinn AS et al. Hydrochloroquine directly reduces the binding of antiphospholipid antibody-β2-glycoprotein I complex to phospholipid bilayers. Blood 2008; 112: 1687-1695. Go to original source... Go to PubMed...
    77. Suarez IM, Diaz RA, Aguayo CD et al. Correction of severe thrombocytopenia with choroquine in the primary antiphospholipid syndrome. Lupus 1996; 25: 81-83. Go to original source... Go to PubMed...
    78. Hotlan SG, Knox SK, Terreri A. Use of fondaparinux in patient with antiphospholipid syndrome and heparin-associated thrombocytopenia. J Thromb Haemost 2006; 4: 1632-1634. Go to original source... Go to PubMed...
    79. Athar U, Husain J, Hudson J et al. Prolonged half-life od argatroban in patients with renal dysfunction and antiphospholipid antibody syndrome being treated for heparin-induced thrombocytopenia. Am J Hematol 2007; 83: 245-246. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.